Millipore Sigma Vibrant Logo

233553 COCO, Human, Recombinant

COCO, Human, Recombinant consists of amino acids 23-189 and is expressed in E. coli with an N-terminal methionine. Inhibits BMP-4 induced activity in MC3T3-E1 cells. ED₅₀ = 0.15-0.75 µg/ml.

COCO, Human, Recombinant: SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: DAND5 Dante CKTSF1B3

233553
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

Purity
≥95% by SDS-PAGE

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
233553-50UG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Glasflasche 50 μg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewRecombinant, human COCO consisting of amino acids 23-189 and expressed in E. coli with an N-terminal methionine. Inhibits BMP-4 induced activity in MC3T3-E1 mouse osteoblastic cells. ED 50 = 0.15-0.75 µg/ml. Human COCO, at the amino acid sequence level, is 60% and 24% identical with mouse and Xenopus COCO, respectively.
      Catalogue Number233553
      Brand Family Calbiochem®
      SynonymsDAND5 Dante CKTSF1B3
      References
      ReferencesBaron, M.H., 2005. Exp. Hematol. 33, 1015. Katoh, M. and M. Katoh. 2005. Int. J. Mol. Med. 15, 885. Kishigami, S. and Y. Mishina. 2005. Cytokine Growth FactorRev. 16, 265. AvsianKretchmer, O. and A.J.W. Hsueh. 2004. Mol. Endocrinol. 18, 1. De Robertis, E.M. and H. Koruda. 2004. Annu. Rev. Cell Dev. Biol. 20, 285. Katoh, M. and M. Katoh. 2004. Oncol. Rep. 12, 423. Bell, E., et al. 2003. Development 130, 1381. Pearce, J.J. et al., 1999. Dev. Biol. 209, 98.
      Product Information
      FormLiquid
      FormulationLyophilized from 0.2 µm sterile-filtered Acetonitrile, TFA, BSA.
      Quality LevelMQ100
      Applications
      Biological Information
      Biological activityED₅₀ = 0.15 0.75 µg/ml in the presence of 50 ng/ml of rhBMP-4 as measured by its ability to inhibit BMP-4-induced activity in MC3T3-E1 mouse osteoblastic cells.
      Purity≥95% by SDS-PAGE
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C or for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      233553-50UG 04055977217902

      Documentation

      COCO, Human, Recombinant Analysenzertifikate

      TitelChargennummer
      233553

      Literatur

      Übersicht
      Baron, M.H., 2005. Exp. Hematol. 33, 1015. Katoh, M. and M. Katoh. 2005. Int. J. Mol. Med. 15, 885. Kishigami, S. and Y. Mishina. 2005. Cytokine Growth FactorRev. 16, 265. AvsianKretchmer, O. and A.J.W. Hsueh. 2004. Mol. Endocrinol. 18, 1. De Robertis, E.M. and H. Koruda. 2004. Annu. Rev. Cell Dev. Biol. 20, 285. Katoh, M. and M. Katoh. 2004. Oncol. Rep. 12, 423. Bell, E., et al. 2003. Development 130, 1381. Pearce, J.J. et al., 1999. Dev. Biol. 209, 98.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision20-Sepmtember-2011 RFH
      SynonymsDAND5 Dante CKTSF1B3
      DescriptionRecombinant, human COCO consisting of amino acids 23-189 and expressed in E. coli with an N-terminal methionine. Inhibits BMP-4 induced activity in MC3T3-E1 mouse osteoblastic cells. ED 50 = 0.15-0.75 µg/ml. Human COCO, at the amino acid sequence level, is 60% and 24% identical with mouse and Xenopus COCO, respectively.
      FormLiquid
      FormulationLyophilized from 0.2 µm sterile-filtered Acetonitrile, TFA, BSA.
      Purity≥95% by SDS-PAGE
      Biological activityED₅₀ = 0.15 0.75 µg/ml in the presence of 50 ng/ml of rhBMP-4 as measured by its ability to inhibit BMP-4-induced activity in MC3T3-E1 mouse osteoblastic cells.
      SolubilityReconstitute to 200 µg/ml in sterile 4 mM HCI containing at least 0.1% human or bovine serum albumin.
      Storage -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage. Stock solutions are stable for up to 1 month at 4°C or for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesBaron, M.H., 2005. Exp. Hematol. 33, 1015. Katoh, M. and M. Katoh. 2005. Int. J. Mol. Med. 15, 885. Kishigami, S. and Y. Mishina. 2005. Cytokine Growth FactorRev. 16, 265. AvsianKretchmer, O. and A.J.W. Hsueh. 2004. Mol. Endocrinol. 18, 1. De Robertis, E.M. and H. Koruda. 2004. Annu. Rev. Cell Dev. Biol. 20, 285. Katoh, M. and M. Katoh. 2004. Oncol. Rep. 12, 423. Bell, E., et al. 2003. Development 130, 1381. Pearce, J.J. et al., 1999. Dev. Biol. 209, 98.